CAJ | 학술논문

目的：探讨仙灵骨葆胶囊治疗绝经后骨质疏松症（ PMOP）的临床疗效及其对血清护骨素／细胞核因子κB受体活化因子配体（ RANKL）的影响。方法患者随机分为2组，对照组口服元素钙600 mg? d-1和维生素D 0.25μg? d-1，在对照组基础上，试验组加用仙灵骨葆胶囊（1.5 g bid，口服）。疗程均为6个月。观察2组的临床疗效，测定骨密度，检测血清护骨素、RANKL水平。结果试验组，临床总有效率（93.30％）明显优于对照组（70.00％， P＜0.05）。试验组，骨密度的提高（0.97±0.10，0.79±0.10）明显优于对照组（0.77±0.10，0.62±0.10）（ P＜0.05）。试验组，血清护骨素水平明显高于对照组（142.24±6.54 vs 119.18±5.71），而 RANKL 水平明显低于对照组（6.62±1.04 vs 8.46±1.63，P＜0.05）。结论仙灵骨葆胶囊治疗PMOP具有良好的临床疗效，其作用机制可能与上调血清护骨素的表达、下调RANKL的表达有关。
목적：탐토선령골보효낭치료절경후골질소송증（ PMOP）적림상료효급기대혈청호골소／세포핵인자κB수체활화인자배체（ RANKL）적영향。방법환자수궤분위2조，대조조구복원소개600 mg? d-1화유생소D 0.25μg? d-1，재대조조기출상，시험조가용선령골보효낭（1.5 g bid，구복）。료정균위6개월。관찰2조적림상료효，측정골밀도，검측혈청호골소、RANKL수평。결과시험조，림상총유효솔（93.30％）명현우우대조조（70.00％， P＜0.05）。시험조，골밀도적제고（0.97±0.10，0.79±0.10）명현우우대조조（0.77±0.10，0.62±0.10）（ P＜0.05）。시험조，혈청호골소수평명현고우대조조（142.24±6.54 vs 119.18±5.71），이 RANKL 수평명현저우대조조（6.62±1.04 vs 8.46±1.63，P＜0.05）。결론선령골보효낭치료PMOP구유량호적림상료효，기작용궤제가능여상조혈청호골소적표체、하조RANKL적표체유관。
Objective To explore the curative effect of Xianlinggubao capsule in the treatment of postmenopausal osteoporosis ( PMOP) and its effect on osteoprotegerin , receptor activator of nuclear factor -κB ligand ( RANKL) in serum.Methods The patients in control group was trea-ted with calcium 600 mg? d-1 and vitamin D 0.25 μg? d-1 orally.The patients in trial group was added Xianlinggubao capsule 1.5 g bid orally on the base of treatment in control group .Treatment lasted for 6 months. After the treatment , the clinical efficacy was observed .The bone mineral density ( BMD ) was detected and the level of osteoprotegerin′s and RANKL′s were determined.Results The clinical total effective rate of trial group ( 93.30%) was significantly better than control group (70.00%,P<0.05).BMD of trial group(0.97 ±0.10, 0.79 ±0.10) was improved better than control group ( 0.77 ±0.10 , 0.62 ±0.10 ) , the difference was statistically significant ( P <0.05 ) .The expression level of osteoprotegerin in trial group was significantly higher than control group (142.24 ±6.54 vs 119.18 ±5.71 ).And the expression level of RANKL was significantly lower than control group ( 6.62 ±1.04 vs 8.46 ±1.63 ) , the difference was statistically significant ( P <0.05 ) . Conclusion There was a good clinical effect to treat PMOP with Xianlinggubao capsule , and its mechanism may be related to upregulate the expression of osteoprotegerin , downregulate the expression of RANKL.